7th Annual MarketsandMarkets

Biomarker and Companion Diagnostics Conference

16th - 17th June 2022

Double Tree by Hilton San Diego- Mission Valley

Leveraging next gen technologies beyond conventional biomarker drug discovery

The 7th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference scheduled to be held on 16th - 17th June 2022 in San Diego, CA would address the gaps between early stage biomarker development and the commercialization stage of biomarkers.

Tag Line
30+ experts from academia and industry will be presenting their current work in Biomarkers, Latest updates on regulatory guidelines and approvals, Cancer biomarker validation for clinical application, Biomarkers and Personalized Medicine, Impact of Big data in translational biomarker research and Future of Companion Diagnostics
Tag Line
Opportunity to develop long-lasting business relationships and networking opportunities with researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies, Universities, and Research institutes.
Tag Line
Over 20 presentations, round-tables, and panel discussions focused on the key opportunities and challenges in biomarker research, from precision medicine and companion diagnostics through to digital biomarkers and clinical trials.

This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers, Precision Medicine and Big Data. Regarding commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers..

CO-LOCATED CONFERENCES

4th Annual MarketsandMarkets  Next-Gen Microbiome and Probiotics Conference

WHAT TO EXPECT

  • Commercialization of CDx
  • Proteomics and Genomics based Biomarkers
  • Biomarker Drug Discovery and Assay Development
  • Multiplex Companion Diagnostics and Regulatory Guidelines
  • Design of clinical trials in CDx
  • Digital Biomarkers, Predictive Biomarkers, Precision Medicine and Big Data
  • Clinical Applications of Biomarkers in Immuno-Oncology, Neurology and Inflammatory Diseases

Researchers, scientists, clinicians, academicians and professionals from Pharmaceutical companies, Bio-pharma companies & Universities and Research institutes working in:

  • Biomarker discovery/development
  • Translational research
  • Clinical Biomarker
  • Biomarkers in IO and Neurological disorders
  • Imaging Biomarkers
  • Pathology
  • Companion Diagnostics
  • Biomarker Imaging
  • Proteomics Biomarkers
  • Experimental Medicine
  • Data Science
  • Biomarkers in Clinical Discovery
  • Immuno-oncology/Neuroscience Drug Discovery
  • Diagnostic Biomarkers development
  • Personalized Medicine
  • Immunology Biomarkers

CONFERENCE AGENDA

Registration

08:15 - 08:55

Opening Keynote from MarketsandMarkets

08:55 - 09:00

Opening Remarks from the Chairman

 Paul Kassner

Paul Kassner, Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics

09:00 - 09:05

Keynote Presentation: Implementing Biomarker Strategy in Late-Stage Clinical Trials

Chetan Deshpande

Chetan Deshpande , Director, Biomarker Clinical Assay Lead in Global Product Development , Pfizer

09:05 - 09:40

Biomarkers in Clinical & Translational Development: Drug Discovery and Assay Development

Enhanced Biomarker Discovery and Validation Using TMT® Proteomics

Ian Pike

Ian Pike, Chief Scientific Officer, Proteome Sciences PLC

09:40 - 10:15

Multiplex IHC/IF_Applications in Clinical Trials and Diagnostics

Buer Song

Buer Song, CEO , iCura Diagnostics

10:15 - 10:50

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:50 - 11:35

Flow cytometry for development of clinical biomarkers and CDx

Scott J. Bornheimer

Scott J. Bornheimer, Associate Director, Medical & Scientific Affairs, BD Biosciences

11:35 - 12:10

Blood and skin biomarkers from a first-in-human study of RPT193 - an oral CCR4 antagonist for the treatment of atopic dermatitis

 Paul Kassner

Paul Kassner, Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics

12:10 - 12:45

Novel approach for high sensitivity quantification of Antisense Oligonucleotides (ASOs) for pharmacokinetic (PK) characterization

Shilpi Mahajan

Shilpi Mahajan, Senior Scientist, Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca

12:45 - 13:20

Lunch and Poster Presentation | One-to-One Networking Meetings

13:20 - 14:20

Innovations in Biomarker Research: Digital Biomarkers, Precision Medicine and Big Data

Hypoxia biomarkers: Personalising cancer treatments by targeting hypoxia

Joely Irlam

Joely Irlam , CEO , ManTRa Diagnostics

14:20 - 14:55

Artificial Intelligence, Explainability, and Transparency in Machine Learning Based Diagnostic Tests

Robert Georgantas

Robert Georgantas , Chief Scientific Officer , Biodesix

14:55 - 15:30

Bigger data = better data: Detect 7000 proteins at once with high throughput to optimize biomarker discovery

Joe Gogain

Joe Gogain , Associate Director of Clinical Research and Development, Somalogic

15:30 - 16:05

Evening Refreshments and Poster Presentation | One-to-One Networking Meetings

16:05 - 16:45

Biosignal Processing Units (BPUs): A Merger of Biology and Semiconductors

Francie Barron

Francie Barron, Vice President, Innovation Partnerships, Cardea Bio

16:45 - 17:20

Closing Remarks from the Chairman

 Paul Kassner

Paul Kassner, Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics

17:20 - 17:25

Drinks Reception & Networking

17:25 - 19:00

Registration

08:15 - 08:55

Welcome note from MarketsandMarkets

08:55 - 09:00

Opening Remarks from the Chairman

 Paul Kassner

Paul Kassner, Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics

09:00 - 09:05

Keynote Presentation: Precision Medicine Informed Immuno-Oncology as Mono- and Combination Therapy is Transforming Cancer Treatment

09:05 - 09:40

From Biomarkers to CDx: Strategies to accelerate CDx development and Commercialization

Conundrums of CDx Commercialization

Philip Measor

Philip Measor, Assistant Professor, Whitworth University

09:40 - 10:15

New molecular strategies for successful development of Immuno-Therapies

Andrea Giuliani

Andrea Giuliani , Director, Business Development, Oncology and Precision Diagnostics, QIAGEN

10:15 - 10:50

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:50 - 11:35

The use of reference materials to accelerate CDx development and commercialization

Ronald Vos

Ronald Vos , Business Development Manager , SensID

11:35 - 12:10

From Multiplex discovery to IVD Diagnostics – A Biomarker journey

Claire Huguet

Claire Huguet , Head, Biomarker Services , Randox Biosciences

12:10 - 12:45

The Diagnostic Toolkit for EBV-Associated Malignancies: Implications for Present and Future

Yisrael Katz

Yisrael Katz, Senior Medical Director , Viracta Therapeutics, Inc.

12:45 - 13:20

Lunch and Poster Presentation | One-to-One Networking Meetings

13:20 - 14:20

BREAK OUT SESSION- Overcoming resistance to current cell therapy products

John Rossi

John Rossi, Vice President, Head, Translational Medicine, , Syncopation Lifesciences

14:20 - 14:55

Chromosome 9p Loss Drives Immune Evasion and Checkpoint-Inhibitor Resistance in HPV— HNSC

Scott Lippman

Scott Lippman , Director , Moores Cancer Center

14:55 - 15:30

Closing Remarks from the Chairman

 Paul Kassner

Paul Kassner, Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics

15:30 - 15:35

End of Conference

15:35 - 15:40

CONFERENCE SPEAKERS

ADVISORS

John Rossi

John Rossi

Vice President, Head, Translational Medicine, , Syncopation Lifesciences

SPEAKERS

John Rossi

John Rossi

Vice President, Head, Translational Medicine, , Syncopation Lifesciences

Jessica McDonough

Jessica McDonough

Co-Founder, Attivare Therapeutics

Yisrael Katz

Yisrael Katz

Senior Medical Director , Viracta Therapeutics, Inc.

Francie Barron

Francie Barron

Vice President, Innovation Partnerships, Cardea Bio

 Paul Kassner

Paul Kassner

Senior Vice President, Quantitative & Computational Biology , RAPT Therapeutics

Shilpi Mahajan

Shilpi Mahajan

Senior Scientist, Clinical Pharmacology and Quantitative Pharmacology, AstraZeneca

Philip Measor

Philip Measor

Assistant Professor, Whitworth University

Andrea Giuliani

Andrea Giuliani

Director, Business Development, Oncology and Precision Diagnostics, QIAGEN

Joe Gogain

Joe Gogain

Associate Director of Clinical Research and Development, Somalogic

Jayne Russell

Jayne Russell

Project Manager, Randox Biosciences

Buer Song

Buer Song

CEO , iCura Diagnostics

Ronald Vos

Ronald Vos

Business Development Manager , SensID

Scott Lippman

Scott Lippman

Director , Moores Cancer Center

Joely Irlam

Joely Irlam

CEO , ManTRa Diagnostics

Claire Huguet

Claire Huguet

Head, Biomarker Services , Randox Biosciences

Robert Georgantas

Robert Georgantas

Chief Scientific Officer , Biodesix

Chetan Deshpande

Chetan Deshpande

Director, Biomarker Clinical Assay Lead in Global Product Development , Pfizer

Scott J. Bornheimer

Scott J. Bornheimer

Associate Director, Medical & Scientific Affairs, BD Biosciences

ENQUIRE NOW

SPONSORS

PARTNERS

LOCATION

Venue

Double Tree by Hilton San Diego- Mission Valley

PAST EVENT GALLERY